News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

David Miklos, MD, PhD

Articles by David Miklos, MD, PhD

7 experts are featured in this series.

Clinical Scenario: Treatment Decisions for a 53-Year-Old w/ R/R LBCL

ByMatthew A. Lunning, DO,Loretta J. Nastoupil, MD,Brian T. Hill, MD, PhD,Christopher R D'Angelo, MD,David Miklos, MD, PhD,Nathan Denlinger, DO, MS ,Amitkumar Mehta, MD

January 22nd 2026

7 experts are featured in this series.

Clinical Scenario: Treatment Decisions for a 31-Year-Old w/ R/R LBCL

ByMatthew A. Lunning, DO,Loretta J. Nastoupil, MD,Brian T. Hill, MD, PhD,Christopher R D'Angelo, MD,David Miklos, MD, PhD,Nathan Denlinger, DO, MS ,Amitkumar Mehta, MD

January 22nd 2026

7 experts are featured in this series.

Optimizing CAR T-Cell Access & Delivery in R/R LBCL

ByMatthew A. Lunning, DO,Loretta J. Nastoupil, MD,Brian T. Hill, MD, PhD,Christopher R D'Angelo, MD,David Miklos, MD, PhD,Nathan Denlinger, DO, MS ,Amitkumar Mehta, MD

January 15th 2026

7 experts are featured in this series.

Navigating 2L Treatment Pathways in LBCL

ByMatthew A. Lunning, DO,Loretta J. Nastoupil, MD,Brian T. Hill, MD, PhD,Christopher R D'Angelo, MD,David Miklos, MD, PhD,Nathan Denlinger, DO, MS ,Amitkumar Mehta, MD

January 15th 2026

7 experts are featured in this series.

CAR T Outcomes in LBCL: US Flatiron EMR Real-World Findings

ByMatthew A. Lunning, DO,Loretta J. Nastoupil, MD,Brian T. Hill, MD, PhD,Christopher R D'Angelo, MD,David Miklos, MD, PhD,Nathan Denlinger, DO, MS ,Amitkumar Mehta, MD

Published: January 8th 2026 | Updated: January 9th 2026

7 experts are featured in this series.

Real-World Treatment Patterns in R/R LBCL: Insights from Flatiron Data Pre & Post 2L CAR T Approval

ByMatthew A. Lunning, DO,Loretta J. Nastoupil, MD,Brian T. Hill, MD, PhD,Christopher R D'Angelo, MD,David Miklos, MD, PhD,Nathan Denlinger, DO, MS ,Amitkumar Mehta, MD

January 8th 2026

7 experts are featured in this series.

ZUMA-7 Final Analysis: Key Efficacy and Safety Findings

ByMatthew A. Lunning, DO,Loretta J. Nastoupil, MD,Brian T. Hill, MD, PhD,Christopher R D'Angelo, MD,David Miklos, MD, PhD,Nathan Denlinger, DO, MS ,Amitkumar Mehta, MD

Published: December 19th 2025 | Updated: December 23rd 2025

7 experts are featured in this series.

TRANSFORM + Long-Term Follow-Up ASH 2025 Insights: Durability, Survival, and Safety Updates

ByMatthew A. Lunning, DO,Loretta J. Nastoupil, MD,Brian T. Hill, MD, PhD,Christopher R D'Angelo, MD,David Miklos, MD, PhD,Nathan Denlinger, DO, MS ,Amitkumar Mehta, MD

December 19th 2025

Latest Updated Articles

ZUMA-7 Final Analysis: Key Efficacy and Safety Findings
Published: December 19th 2025 | Updated: December 23rd 2025
CAR T Outcomes in LBCL: US Flatiron EMR Real-World Findings
Published: January 8th 2026 | Updated: January 9th 2026

Trending on CancerNetwork

FDA Removes Black Box Warning for Breast Cancer and Other Indications on HRT Products

How Tolerable is Pembrolizumab/Paclitaxel/Bevacizumab in PROC?

Where Does KEYNOTE-B96 Regimen Fit in Pretreated Ovarian Cancer?

Neoadjuvant Therapy Improves Survival in Upfront Resectable PDAC Subtype

FDA Accepts NDA for Iberdomide Combination in R/R Multiple Myeloma